

# **University of Rochester**

## **Embryonic Stem Cell Research Oversight Committee (ESCRO) Application Form**

A. General Information						
Reason for Submission to ESCRO:						
■ New Project    ■ Response to Comments    ■ Reconsideration    ■ Disapproval resubmission						
Modification Renewal Renewal Response to Audit						
Principal Investigator						
First Name						
Last Name						
Degree(s)						
Experience/Number of Years						
Alternative Contact with Knowledge of this Protocol  First Name  Last Name						
First Name Last Name						
School Department Division						
Benoof Bepartment Bivision						
Phone Fax Email						
Office Address Mailing Address (if different from office address)						
Project Title:						
Froject Title.						
Source of Support (Please check all that apply)						
Federal Federal						
State State						
Commercial Commercial						
Foundation						
Internal						
U Other: Please Specify:						
Name of Sponsor(s)						
Name of Sponsor(s)						
Grant #:						
Grant title:						
Please use additional pages if necessary to list relevant grants support or external sponsorship.						

B. Qualifications of Listed Investigators-Please list the names, titles, department and qualifications of the principal Investigator and each of the listed co-investigators. An NIH bio-sketch should also be included for each individual.
C. Description of Facilities
On Campus (i.e. University owned or rented) List Building(s) & Room Number(s):
Off Campus (non University owned or rented) Address:
D. Experimental Background and Design Please provide a brief non-technical description of the background, aims and design of your research proposal. This description should also include a brief summary as to how the research is intended to benefit human health and/or advance science and medical knowledge. This description should be brief; please limit it to this page, and one additional page if needed.

E. Cate	egories of	research that best describes this project (Note more than one category may apply)					
f your research proposal falls into categories 1 through 5, then it should be submitted to the ESCRO Committee							
	AFTER review and approval by other relevant review committees. E.g. the IRB, IACUC, rDNA. Include a opy of each of these approvals. (See J.)						
1.		earch limited to in vitro procedures involving de-identified human stem cell lines, other than					
	hES cell	s whereby:					
	(i)	the cells were obtained by a process approved by an institutional review board to ensure that					
	(1)	donor(s) provided voluntary informed consent in accordance with then current federal and state					
		regulations and guidelines), and					
	(ii)	the call lines and any corresponding information are anonymous or are coded in such a manner					
	(ii) the cell lines and any corresponding information are anonymous or are coded in such a manner that the donor(s) cannot be identified (i.e. by the investigators or others) directly or indirectly						
		through identifiers linked to the donor(s), and					
	<b></b>						
	(111)	a written agreement has been obtained from the source of the cell lines and any corresponding confidential (e.g. medical record) information station that the identity of the donor(s) will not					
		be released to the investigator under any circumstances.					
2.		earch limited to in vitro procedures involving hES cell lines that are listed on the NIH human nic Stem Cell Registry					
	Ellioryo	inc Stein Cen Registry					
3.	_	man subject research involving autologous or allogenic non-embryonic stem cell					
	transplai	ntation intended for a hematopoietic indication.					
4.	□ Hn	man subject research involving autologous or allogenic non-embryonic stem cell					
••		ntation intended for a non-hematopoietic indication.					
_							
5.		earch testing the function and character of human embryonic stem cells or their derivatives by int into non USDA regulated species (cold blooded animals, rats, mice and birds)					
	transpiai	it into non USDA regulated species (cold blooded animals, rats, infec and birds)					
6.		arch testing the function and character of human tissue stem cells by transplant into non USDA					
	regulated	d species (cold blooded animals, rats, mice and birds)					
7.	Rese	earch testing the function and character of human embryonic stem cells or their derivatives or					
		testing the function and character of human adult tissue stem cells by transplant into non USDA					
	regulated	d species (larger animals including primates)					
8.	Rese	arch involving human stem cells derived from umbilical cord blood, placenta or fetal tissue.					
9. Human embryonic stem cells NOT on the NIH registry – For research of this nature, please							
	contact	the ESCRO Office at (escro@urmc.rochester.edu)					
10. Other (please describe)							
For research falling into category 8 or 9, the investigator must submit the proposal to the ESCRO							
		sittle first for review by the convened ESCRO Committee. This submission should be done					
		onically and be accompanied by the proposed IRB research protocol and consent form tent(s), if applicable (i.e., the proposed research involves human subjects); proposed IACUC					
		ch protocol, if applicable (i.e. the proposed research involves animal subjects); Materials					

Transfer Agreement, if applicable (i.e., for human stem cell lines imported into the University) and if applicable the external sponsor's clinical protocol and investigator's brochure.

### **F. Provenance of Federally Approved Cell Lines**

1. Please provide the requested information regarding the source of the cell lines: (see <a href="http://stemcells.nih.gov/research/registry/for">http://stemcells.nih.gov/research/registry/for</a> information)

Vendor	NIH	Registry	&	Vendor	UCLA	MTA	Number of lines
	Numb	er			Number		
1.							
2.							
3.							
4.							

#### G. Additional Questions for Research Involving Human Embryonic Stem Cells

- 1. Why are human embryonic stem cells, rather than non-human embryonic stem cells, necessary for use in this research?
- 2. Why is the use of human embryonic stem cells preferable to the use of tissue-derived stem cells in this research?
- H. For research involving the introduction of human stem cells into animals, each of the following animal research questions should be addressed:

#### If not applicable got to section I

1. Please list the animals and include the age and quantity of each animal necessary to accomplish the research goals.

Animal/Age	Number of animals
1.	
2.	
3.	

2. Please briefly outline any animal experiments involving human stem cell implantation. Include specific information as to the species, sites and ages at xenograft.

	3.	Will cells be implanted into non-human fetuses?   Yes   No If yes, please answer the following:
		A.   Yes No: Will hESC derivatives, HESC cells, or other pluripotent cells be introduced into non-human fetuses and allowed to develop into adult chimeras? If so, please explain the extent of human contribution to the resulting animal.
		B. Yes No: Will this protocol include the introduction of hESCs into non-human primate blastocysts?
		C. Yes No: Will this protocol include the introduction of hESCs into human blastocysts?
		D. Please outline anticipated potential consequences of the human contributions to the resulting chimeras. What is the anticipated effect of the human stem cells on the animal's anatomy, physiology and species-specific behavior? Consideration of any major functional contributions to the brain should be addressed specifically.
	4.	Will the animals be allowed to breed? If so, please explain and provide a scientific justification for allowing the animals to breed. YesNo
:	5.	Why are human stem cells required for this project instead of cells from other primates or animals?
,	6.	How will any unanticipated results be handled, identified, managed, documented and reported to the IACUC and the ESCRO?
I. P	riv	acy/Confidentiality of Donor
		Are the stem cells being used in this research linked to any information whereby it would be possible for you to identify the donors of the original blastocyst?   Yes No NA
		Are the stem cells linked to any information whereby it would be possible for the <u>source institution</u> to link the cells to the donors of the original blastocyst?   Yes  No  NA

J. Approvals from other committees within the University of Rochester Please indicate approvals obtained from other committees within the University. Copies of approval must be submitted fro each applicable committee review and approval.
RSRB Review Board (Please indicate if approval was exempt, expedited, or full board)
☐ Institutional Biosafety Committee-recombinant DNA (IBC-rDNA)
☐ Institutional Animal Care and Use Committee (UCAR)
☐ Dean's Office, prior Scientific Review and Approval
K. External Collaborations  Guidelines: Describe any arrangement with or procedures conducted by non-University investigators. If there are more than two, please list and describe on separate page.
<ol> <li>[Name of collaborating institution]         [Name of collaborator, degree]         [Title]         [Mailing address]     </li> </ol>
2. [Name of collaborating institution] [Name of collaborator, degree] [Title] [Mailing address]
L. Approvals from IRB and ESCRO committees outside the University of Rochester Please indicate approvals obtained from IRB and ESCRO committees outside the University. Copies of approval letters should be submitted for each respective committee review and approval.
M. Materials Transfer Agreement University of Rochester researchers must execute, with the University Office of Research Project Administration, a Material Transfer Agreement prior to obtaining any human stem cell lines from an external entity.
Is there a Materials Transfer Agreement for this study?   Yes No NA
If yes, a copy of this agreement must be submitted.
N. Conflict of Interest  Does the principal investigator or any co-investigator or research coordinator involved in this study (or in aggregate with his/her spouse, dependents or members of his/her household):  a. possess an equity interest in the entity that either sponsors this research or owns the technology being evaluated that exceeds 5% ownership interest or a current value of \$10,000?  Yes No

<ul> <li>b. receive salary, royalty or other payments from the entity that either sponsors this reso owns the technology being evaluated that is expected to exceed \$10,000 per year? You not be an agreement with the University or an external entity that would entitle sharing cut future commercial proceeds related to the technology being evaluated (e.g., royalties the license agreement)? Yes No</li> </ul>					
				d. have a	financial relationship with a start-up company that has an option or license to University chester technology being evaluated in this study? Yes No
-	above, please submit detailed information including who has this involvement or conflict sure has been made to the Conflicts Committee.				
O. Investigator's Cer	tification				
	• I have reviewed this protocol submission in its entirety and I am fully cognizant of and in agreement with, all submitted statements.				
• I have adequate resources and facilities to carry out the proposed research.					
	omply with the current state and federal regulations and University of Rochester ESCRC tee requirements governing this research.				
	nsure that all individuals associated with this project have the appropriate credentials to the portion of the study in which they are involved.				
	nsure that all co-investigators, and other personnel assisting in the conduct of this research even been provided a copy of the entire current version of the research protocol and are fully				

• I will respond promptly to all requests for information or materials solicited by the ESCRO Committee.

informed of the current (a) study procedures (including procedure modifications); (b) potential risks associated with the conduct of this study and the steps to be taken to prevent or minimize these potential risks; (c) data and record-keeping requirements; and (d) the current approval status

• I will maintain adequate, current, and accurate records of research data, outcomes, and adverse events (if applicable) to permit an ongoing assessment of this research project.

P. Signature of Investigator:	Date:	

of the research study.

I certify that I have read and will comply with the responsibilities outlined in Section O. The actual signature of the investigator is required. Please contact the ESCRO Office to obtain a protocol number for this application and submit the signed form to the ESCRO office.

The ESCRO Application Form must be submitted electronically to (Katie\_Scoville@urmc.rochester.edu). If attachments cannot be converted to an electronic format, they may be faxed to 585-273-1450 or delivered to: Chelsea Costanzo (Phone: 585-273-1447) or Katie Scoville (Phone: 585-273-1441) 575 Elmwood Avenue, Room 2-9644, Box 633, Rochester, NY 14642. Prior to start of work a signed copy must also be submitted.